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Abstract
Targeting tumor-initiating, drug-resistant populations of cancer stem cells (CSC) with phytochemicals is a novel 
paradigm for cancer prevention and treatment. We herein employed a phenotypic drug discovery approach coupled to 
mechanism-of-action profiling and target deconvolution to identify phenolic components of extra virgin olive oil (EVOO) 
capable of suppressing the functional traits of CSC in breast cancer (BC). In vitro screening revealed that the secoiridoid 
decarboxymethyl oleuropein aglycone (DOA) could selectively target subpopulations of epithelial-like, aldehyde 
dehydrogenase (ALDH)-positive and mesenchymal-like, CD44+CD24−/low CSC. DOA could potently block the formation of 
multicellular tumorspheres generated from single-founder stem-like cells in a panel of genetically diverse BC models. 
Pretreatment of BC populations with noncytotoxic doses of DOA dramatically reduced subsequent tumor-forming capacity 
in vivo. Mice orthotopically injected with CSC-enriched BC-cell populations pretreated with DOA remained tumor-free for 
several months. Phenotype microarray-based screening pointed to a synergistic interaction of DOA with the mTOR inhibitor 
rapamycin and the DNA methyltransferase (DNMT) inhibitor 5-azacytidine. In silico computational studies indicated that 
DOA binds and inhibits the ATP-binding kinase domain site of mTOR and the S-adenosyl-l-methionine (SAM) cofactor-
binding pocket of DNMTs. FRET-based Z-LYTE™ and AlphaScreen-based in vitro assays confirmed the ability of DOA to 
function as an ATP-competitive mTOR inhibitor and to block the SAM-dependent methylation activity of DNMTs. Our 
systematic in vitro, in vivo and in silico approaches establish the phenol-conjugated oleoside DOA as a dual mTOR/DNMT 
inhibitor naturally occurring in EVOO that functionally suppresses CSC-like states responsible for maintaining tumor-
initiating cell properties within BC populations.
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Introduction
Cancer relapse and metastatic dissemination can occur after 
the primary tumor has been eradicated by surgical removal, 
chemotherapy, radiation or targeted therapy. Such life-threaten-
ing phenomena can be largely attributed to the incomplete 
elimination of so-called cancer stem cells (CSC), a particularly 
aggressive type of malignant cell defined in terms of functional 
traits of self-renewal, differentiation, therapy resistance and 
tumor/metastasis-initiating capacity (1–5). Accordingly, the rela-
tive abundance of CSC populations correlates with unfavorable 
outcomes and is an independent risk factor for tumor recur-
rence and post therapy progression.
The CSC model has created new opportunities for cancer ther-
apy. In the last decade, more than 150 therapeutic approaches 
have been envisioned to deplete the CSC pool via targeting of CSC 
surface antigens, CSC-associated oncoproteins, stemness regu-
lation pathways or inhibiting CSC-related drug resistance path-
ways (6,7). Unfortunately, progress in the medical development 
of CSC-direct approaches has been disappointing, and no bona 
fide anti-CSC drugs have entered the clinical use. One reason for 
such failure might relate to the widely accepted belief that genet-
ically predefined populations of treatment-refractory CSC should 
be viewed as the sole source of minimal residual disease, tumor 
recurrence and metastasis. While the actual contribution of phe-
nomena such as epithelial-to-mesenchymal transition and dedif-
ferentiation/reprogramming plasticity to the de novo generation 
of CSC during carcinogenesis remains a matter of debate (8–13), it 
is well accepted that conventional therapies would enrich cancer 
tissues with stem cell-like cancer cell populations that remain 
largely refractory to existing therapeutics. Accordingly, the sole 
credible target that could be exploited to prevent the manifest-
ation of CSC would be the biological machinery in charge of the 
epigenetic proclivity of cancer cell populations to generate, main-
tain and perpetuate the so-called CSC-like states.
Plant-derived polyphenols whose consumption has been 
epidemiologically, clinically and experimentally implicated in 
the dietary protection against aging-related chronic diseases, 
including cancer, are potentially useful leads to develop new 
families of anti-CSC drugs (14–18). For instance, curcumin, the 
main polyphenol in turmeric, has been shown to target func-
tional properties of chemotherapy-resistant colon and breast 
CSC subpopulations (19). Sulforaphanes, a family of isothio-
cyanates enriched in cruciferous vegetables such as broccoli, 
cauliflower, kale and cabbage, can inhibit the self-renewal and 
tumor-initiating capacity of CSC (20). Likewise, resveratrol, a 
natural stilbene from a wide variety of plant species includ-
ing grapes, mulberries and peanuts, can inhibit CSC traits (21). 
Another example is the polyphenol genistein, the predominant 
isoflavone in soybean-enriched foods, which has been found to 
reduce the tumor-initiating capacity of CSC (22). Epigallocatechin 
gallate, the most abundant catechin in tea, has been also found 
to reduce CSC-related attributes in various cancers (23).
The ability of the so-called Mediterranean diet to signifi-
cantly decrease the risk of several chronic diseases, including 
breast cancer (BC), has been largely attributed to the unique 
characteristics of extra virgin olive oil (EVOO), the juice from the 
fruits of olive trees obtained solely by mechanical means and 
consumed without further refinement (24–26). In addition to a 
favorable fat composition due to its high content (60–80%) of the 
monounsaturated fatty acid, oleic acid, the other fundamental 
health-related characteristic of EVOO is the presence of a large 
number of phenolic-like compounds (27–29). Of note, unlike 
phenolic acids, phenolic alcohols, tocopherols, flavonoids and 
lignans, which can also be found in many fruits and vegetables 
belonging to different botanical families, the group of complex 
phenol-conjugated compounds named oleosidic secoiridoids or 
oleosides is present only in plants of the Oleacea family includ-
ing the European olive tree (Olea europaea L.). However, despite 
the considerable effort expended on identifying new oleosides 
in O.europaea L.  and determining their chemistry during pro-
cessing and storage of EVOO (30), no studies have explored 
whether such secoiridoids contained in the phenolic fraction of 
cold-pressed EVOO juice have anti-CSC properties.
We now report a phenotypic drug discovery approach cou-
pled to mechanism-of-action profiling and computational-
experimental target deconvolution aimed at identifying and 
characterizing phenol-conjugated oleosidic secoiridoids as a 
new family of EVOO bioactive phytochemicals capable of spe-
cifically and potently suppressing the functional traits of CSC.
Materials and methods
Cell lines
HMLER cells expressing a control shRNA (shCntrl) or an shRNA targeting 
E-cadherin (shEcad) were generated as described (10,31) and maintained 
in a 1:1 mixture of DMEM + 10% (vol/vol) heat-inactivated fetal bovine 
serum (FBS), insulin, hydrocortisone and Clonetics™ MEGM™ (Mammary 
Epithelial Cell Growth Medium). MCF10DCIS.com and SUM-159 cells were 
purchased from Asterand (Detroit, MI), authenticated using short tandem 
repeat DNA fingerprint and passaged in our laboratory by starting a low-
passage cell stock every month up to 6 months after resuscitation. DCIS.
com cells were cultured in DMEM/F12 with l-glutamine supplemented with 
5% horse serum and penicillin/streptomycin. SUM-159 cells were cultured 
in Ham’s F12 with 5% (vol/vol) FBS, 5 μg/mL insulin and 1 μg/mL hydrocorti-
sone. HER2-overexpressing MCF-7/HER2 (clone 18) cells and their matched 
isogenic control (empty vector transfected) MCF-7/neo cells were kindly 
provided by Mien-Chie Hung (The University of Texas MD Anderson Cancer 
Center, Houston, TX) and routinely grown in improved minimum essen-
tial medium (IMEM) containing 5% (vol/vol) FBS and 2 mmol/L l-glutamine. 
T47D and ZR-75-1 were purchased from American Type Culture Collection 
(Manassas, VA), authenticated according to the ATCC guidelines before 
used in this study and grown in IMEM containing 5% (vol/vol) FBS and 
2 mmol/L l-glutamine. Cell lines were regularly screened for Mycoplasma 
contamination using a MycoAlert Mycoplasma Detection Kit (Lonza, 
Verviers, Belgium).
Metabolic status assessment
Cell viability was determined using standard colorimetric MTT-based 
reduction assays.
Mammosphere-forming efficiency
Mammosphere formation assays were conducted as described previously 
(32). Mammosphere-forming efficiency (MSFE) of cells growing in suspension 
Abbreviations 
ALDH  aldehyde dehydrogenase
BC  breast cancer
CSC  cancer stem cells
DNMT  DNA methyltransferase
DOA  decarboxymethyl oleuropein aglycone
EVOO  extra virgin olive oil
FBS  fetal bovine serum
MD  molecular dynamics
MM/GBSA  mechanics/generalized Borne surface area
MSFE  mammosphere-forming efficiency
OA  oleuropein aglycone
OD  optical density
PM  phenotype microarrays
SAM  S-adenosyl-l-methionine. 
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cultures was calculated as the number of mammospheres-like structures 
formed within 7 days divided by the original number of cells seeded and 
expressed as percentages. Refeeding of mammospheres cultures with com-
pounds and/or sphere medium was performed on days 3 and 5.
Tumor xenograft studies
Approximately 2  ×  106 SUM-159 cells were subcutaneously injected into 
the dorsal flanks of female athymic nude mice (4- to 5-week-old mice, 
23–25  g; Harlan Laboratories). The cells were incubated with or without 
DOA or vehicle for 3 days with daily DOA replenishment before injection. 
In both pretreatment regimens, the body weight and diet consumption 
were determined weekly after dosing; tumor size was measured daily with 
electronic calipers, and tumor volume was calculated using the follow-
ing formula: volume (mm3) =  length × width2 × 0.5. The experiments were 
approved by the Institutional Animal Care and Use Committee (IACUC) of the 
Institut d’Investigació Biomèdica de Bellvitge (IDIBELL; Animal Use Protocol 
#6302 authorized by the Animal Experimental Commission of the Catalan 
Government, Barcelona, Spain). Mice were euthanized by cervical dislocation.
Tumor orthotopic studies
SUM-159 cells cultured in nonadherent and nondifferentiating condi-
tions for 48 h were collected by centrifugation, and cells that were visibly 
anoikis-resistant with intact plasma membranes (assessed by trypan blue 
exclusion) were treated with or without graded concentrations of DOA 
for 2 h before being orthotopically implanted (5 × 103 cells) into the sec-
ond right mammary fat pad of female SCID/Beige mice. The mice were 
palpated twice per week, and the tumor volumes were calculated as 
described above.
ALDEFLUOR® activity assay
The ALDEFLUOR® assay was performed as per the manufacturer’s instruc-
tions (StemCell Technologies, Vancouver, BC, Canada), with or without the 
addition of EVOO-PE or purified OA/DOA.
Docking calculations
All docking calculations were performed using Itzamna and Kin (www.
mindthebyte.com), classical docking and blind-docking software tools. 
Protein structures from RSCB PDB were directly employed for docking cal-
culations using the cavities defined by available crystallographic ligands 
where available. Two runs were carried out for each calculation to avoid 
false positives.
Molecular dynamics calculations
Short (1 ns) molecular dynamics (MD) simulations were performed using 
NAMD version 2.10 over the best-docked complexes, which were selected 
based on the interaction energy. The Ambers99SB-ILDN and the GAFF 
forcefield set of parameters were employed for receptors and ligands, 
respectively. The ligand GAFF parameters were obtained using Acpype 
software, whereas the receptor structures were modeled using the leap 
module of Amber Tools. Simulations were carried out in explicit solvent 
using the TIP3P water model with the imposition of periodic boundary 
conditions via a cubic box. Electrostatic interactions were calculated by 
the particle-mesh Ewald method using constant pressure and tempera-
ture conditions. Each complex was solvated with a minimum distance of 
10 Å from the surface of the complex to the edge of the simulation box. 
Na+ or Cl− ions were also added to the simulation to neutralize the overall 
charge of the systems. The temperature was maintained at 300 K using a 
Langevin thermostat, and the pressure was maintained at 1 atm using a 
Langevin Piston barostat. The time step employed was 2 fs. Bond lengths to 
hydrogens were constrained with the SHAKE algorithm. Before production 
runs, the structure was energy minimized followed by a slow heating-up 
phase using harmonic position restraints on the heavy atoms of the pro-
tein. Subsequently, the system was energy minimized until volume equili-
bration, followed by the production run without any position restraints.
Binding free energy analysis
Molecular mechanics/generalized Borne surface area (MM/GBSA) cal-
culations were performed to calculate the binding free energy (∆Gbind) 
of DOAgly and related inhibitors against selected molecular targets. 
MM/GBSA scoring was performed using the MMPBSA.py algorithm within 
AmberTools. The snapshots generated in the 1 ns MD simulation were 
imputed into the post-simulation MM/GBSA calculations of binding free 
energy. Graphical representations were prepared using Visual Molecular 
Dynamics version 1.9.1, LigPlot+ and PLIP version 1.3.0.
mTOR activity/inhibition assays
To characterize the mTOR kinase potency of DOA, PP242 and Torin 2, 
IC50 determinations for FRAP1 (mTOR) were outsourced to Invitrogen 
(Life Technologies) using the FRET-based Z-LYTE™ SelectScreen Kinase 
Profiling Service. To evaluate the phosphorylation status of P70S6K1 
at T389, SUM-159 cells grown to 80–90% confluence were exposed to 
20 μmol/L DOAgly for 0, 30, 180 and 360 min; alternatively, SUM-159 cells 
grown to 80–90% confluence were exposed to graded concentrations of 
DOA (5, 10 and 20  μmol/L) for 1  h. Cells were then collected and sub-
jected to western blot analysis with antibodies against phospho-p70S6K1 
(Thr389) and total p70S6K1 (Cell Signaling Technology, Danvers, MA). F062-
actin (Sigma–Aldrich) was used as loading control.
DNMT activity/inhibition assays
DNMT activity was evaluated in nuclear extracts using the DNMT activ-
ity/inhibition assay (Active Motif, Carlsbad, CA). Briefly, 10 μg of nuclear 
extracts, obtained with the Nuclear Extract Kit (Active Motif, Carlsbad, 
CA), were incubated with 20 μmol/L DOA for 2 h. Optical density (OD) was 
measured on a microplate reader at 450 nm, and DNMT activity (OD/h/mg) 
was calculated according to the following formula: DNMT activity = 1000 × 
(average sample OD −average blank OD)/[protein amount (μg) × incuba-
tion time (h)]. All samples were assayed in duplicate. As positive control, 
nuclear extracts were incubated with 5 μmol/L 5-azacytidine. The effect 
of DOA on the enzymatic activities of recombinant human DNMTs using 
in vitro enzymatic assays was outsourced to BPS Bioscience and carried 
out by following the protocol described in BPS Bioscience DNMT Universal 
Assay Kit (BPS#52035) using a DNMT substrate precoated plate.
Statistical analysis
All statistical analyses were performed using XLSTAT 2010 (Addinsoft™). 
For all experiments, at least two independent biological replicates were 
performed with n ≥ 3 technical replicates per experiment. No statistical 
method was used to predetermine sample size. Investigators were not 
blinded to data allocation. Experiments were not randomized. Data are 
presented as mean ± SD. Two-group comparisons were performed using 
Student’s t-test for paired and unpaired values. Comparisons of means of 
≥3 groups were performed by ANOVA, and the existence of individual dif-
ferences, in case of significant F values at ANOVA, was tested by Scheffé’s 
multiple contrasts. P values < 0.05 were considered to be statistically sig-
nificant (denoted as *). All statistical tests were two sided.
Further details
See Supplementary Material, available at Carcinogenesis Online file for full 
description of details concerning isolation/purification/analytical char-
acterization of EVOO-derived oleosides, synergism studies, mTOR/DNMT 
activity/inhibition assays, RNA isolation, reverse transcription and stem 
cell transcription factors assays.
Results
A crude phenolic extract derived from EVOO 
suppresses epithelial- and mesenchymal-like 
tumorsphere-initiating CSC states
Breast CSC appear to exist in two different, but reversible and 
therefore interchangeable, epithelial (E)- and mesenchymal 
(M)-like states. The former is characterized by the expression 
of aldehyde dehydrogenase (ALDH+), and the latter is character-
ized by a CD44+CD24−/low immunophenotype (13,33). Based on 
our previous studies demonstrating that an EVOO-derived crude 
phenolic extract (EVOO-PE) containing at least twenty differ-
ent phenolic compounds could regulate some stemness traits 
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(29,34,35), we speculated that such EVOO-PE (Figure 1A) might 
target CSC subpopulations irrespective of their E- or M-like 
traits.
The highly aggressive basal/mesenchymal SUM-159 BC cell 
line is commonly employed to test CSC activity of oncology 
drugs because it naturally harbors a significant proportion of 
ALDH+ E-CSC-like cells (36). We found that in the presence of 
a bioactive but noncytotoxic concentration of crude EVOO-PE, 
the proportion of ALDH+ cells in the SUM-159 cell population 
(approx. 25% in nontreated cells) was selectively and signifi-
cantly reduced to levels as low as 8% (Figure  1B). The ALDH+ 
population of SUM-159 cells is known to be solely responsible 
for initiating and maintaining tumorspheres when grown under 
nonadherent/nondifferentiating conditions (37). Thus, we tested 
the relationship between the ability of crude EVOO-PE to reduce 
the number of ALDH+ cells and the intrinsic capacity of SUM-159 
cells to form mammospheres (scored as MSFE) in suspension 
culture. As expected, the MSFE of SUM-159 cells was signifi-
cantly reduced by more than 80% by treatment with EVOO-PE 
(Figure 1B).
We then exploited the landmark observation by Robert 
Weinberg that BC epithelial cell populations experimentally 
induced into epithelial–mesenchymal transition dramatic-
ally and stably increase the proportion of M-like CD44+CD24−/
low CSCs (10), which constitutes a valuable screening method to 
identify agents capable of targeting M-like CSC (31). The MSFE 
of CD44+CD24−/low-enriched HMLERshECad cells was considerably 
greater than that of HMLERshCntrl cells, which mostly failed to 
form bona fide mammospheres (Figure 1C). This acquired ability 
of HMLERshECad to form CD44+CD24−/low-initiated mammospheres 
was completely prevented by EVOO-PE (Figure 1C).
The ability of the various phenolic compounds contained 
in the crude EVOO-PE to suppress BC cell survival and prolifer-
ation as mammospheres was not due to nonspecific cytotoxic 
effects because cell viability of monolayer cultures of SUM-159 
and HMLERshECad cells remained as high as 95% in its presence 
(Figure 1B and C).
A purified form of the complex polyphenol DOA 
strongly suppresses mammosphere formation in a 
panel of established BC cell lines
We have previously performed a qualitative and quantitative 
characterization of the EVOO-PE employed in this study and 
identified that the secoiridoids derivatives of hydroxytyro-
sol linked to elenolic acid and its decarboxymethylated form, 
namely oleuropein aglycone (OA) and decarboxymethyl oleuro-
pein aglycone (DOA), were the most abundant compounds as 
they constituted up to 23 and 46% of total phenolics, respectively 
(29,35). Based on these findings, we hypothesized that the puri-
fied forms of OA and DOA may recapitulate the anti-CSC activity 
of crude EVOO-PE. Procedures for the isolation and purifica-
tion of OA and DOA from EVOO can be found in Supplementary 
Material, Figure S1, available at Carcinogenesis Online.
The luminal BC cell line MCF-7, which has a high MSFE 
level (32), was used to compare the ability of OA and DOA to 
inhibit tumorsphere formation. Micromolar concentrations of 
OA and DOA inhibited MCF-7 mammosphere formation in a 
dose-dependent manner, with the highest dose of OA and DOA 
(20  μmol/L) eliciting greater inhibitory effects than the lowest 
dose (1 μmol/L; Figure 2A). Moreover, whereas OA reduced MSFE 
by up to 50%, DOA dramatically suppressed such efficiency >90% 
at the highest concentration tested (Figure  2A). We therefore 
focused our attention on the ability of DOA to target CSC in a 
wider range of BC models. We first examined whether exposure 
Figure 1. A phenolic-enriched crude olive oil extract inhibits the mammosphere-
initiating capacity of BC CSC-like states. (A) Three-dimensional map of phenolic 
compound separation obtained by HPLC-ESI-TOF in a crude EVOO-PE obtained 
via isolation protocols described in Supplementary material, Materials and 
Methods, available at Carcinogenesis Online. (B) Representative ALDEFLUOR® assay 
to identify SUM-159 cells with high ALDH activity (ALDH+) in the absence or pres-
ence of 10 μg/mL of the crude EVOO-PE for 3 days. The ALDH inhibitor diethylam-
inobenzaldehyde (DEAB) was used as negative control. Monolayer cultures were 
fed with the crude EVOO-PE every other day. Results are representative of two 
technical replicates per n; n = 3 biological replicates. MSFE is expressed as per-
centages means (columns) ± SD (bars); three technical replicates per n; n = 3 bio-
logical replicates. MTT uptake-based measurement of cell viability is expressed 
as percentages uptake (OD570) relative to untreated control cells (=100% cell viabil-
ity). The results are expressed as percentages means (columns) ± SD (bars); three 
technical replicates per n; i = 3 biological replicates. (C) Figure shows represen-
tative light microscope representations (×20 magnification) of mammospheres 
formed by HMLERShControl and HMLERShEcad cells growing in sphere medium for 
7 days in the absence or presence of graded concentrations of EVOO-PE. MSFE 
and MTT calculations were performed as described for SUM-159 cells in the left 
panels; three technical replicates per n; n = 3 biological replicates. (*P < 0.01 and 
**P < 0.001, statistically significant differences from the untreated (control) group).
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to DOA was sufficient to target and suppress the well-recognized 
ability of the HER2 oncogene to augment the tumor-initiating 
capacity of BC cell populations via expansion of the E-like ALDH+ 
CSC population (13,33,37–39). The greater MSFE acquired upon 
HER2 overexpression was completely prevented when cultures 
of MCF-7/HER2 cells were supplemented with DOA (Figure 2B). 
We then explored the effects of DOA for mammosphere inhibi-
tion in four additional BC cell lines: DCIS.com (a basal-like model 
for ductal carcinoma in situ), T47D and ZR-75-1 (two luminal-like 
BC models) and SUM-159. In all cases, DOA significantly reduced 
MSFE relative to untreated controls (Figure 2C).
To corroborate the ability of DOA to target CSC subpopula-
tions regardless of their E- or M-like trait, we first confirmed 
that the ALDH+ cell content of E-like CSC in SUM-159 cell popu-
lations was reduced by approximately 97% by DOA (Figure 3A). 
The ability of CD44+CD24−/low (M-CSC)-enriched HMLERshECad cells 
to form mammospheres was also completely prevented by 
DOA (Figure  3B). To substantiate the bona fide anti-CSC effects 
of DOA, we induced anoikis in SUM-159 cells by plating them 
in culture dishes coated with poly-2-hydroxyethyl methacrylate 
in the absence or presence of DOA for 48 h prior to replating a 
viable fraction of the cell suspension in serum- and DOA-free 
Figure 2. Purified forms of phenolic oleosides inhibit the mammosphere-initiating capacity of BC CSC-like states. (A) MSFE is expressed as percentages means (col-
umns) ± SD (bars); three technical replicated per n; n = 2 biological replicates. (*P < 0.01 and **P < 0.001, statistically significant differences between groups; n.s. not stat-
istically significant). (B) Figure shows representative light microscope images (×20 magnification) of mammospheres formed by MCF-7 and MCF-7/HER2 cells growing 
in sphere medium for 7 days in the absence or presence of 20 μmol/L DOA. MSFE and MTT calculations of suspension/monolayer cultures of MCF-7/HER2 cells growing 
in the absence or presence of 20 μmol/L DOA were performed as described for MCF-7 cells in A; three technical replicates per n; n = 2 biological replicates. (C) MSFE 
calculations were performed as described for MCF-7 cells in A; three technical replicates per n; n = 3 biological replicates. (*P < 0.01 and **P < 0.001, statistically significant 
differences from the untreated (control) group; n.s. not statistically significant).
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mammosphere medium (Figure 3A). The ability of DOA-treated 
anoikis-resistant cultures to form tight spheroids was reduced 
>70% after removal of DOA, and these anoikis-resistant cells 
were characterized by a high prevalence of irregular cell aggre-
gates with lower sphericity than that found in untreated cul-
tures (Figure 3C). All the MSFE-reducing effects were not due to 
nonspecific, cytotoxic effects of DOA, as it had no impact on cell 
viability in any tested BC cell line growing in adherent culture 
(Figures 2B and 3B, and data not shown).
DOA reduces the in vivo tumorigenicity of BC cell 
populations
Because CSC are believed to be responsible for tumor initiation, 
we assessed the impact of DOA for the tumor-seeding ability of 
heterogeneous BC populations in vivo. To do this, we pretreated 
monolayer cultures of SUM-159 cells with either vehicle or 
20 μmol/L DOA for 3 days with daily refeeding of the compound 
(Figure 4A). Subsequently, cells that were fully viable as deter-
mined by trypan-blue exclusion were subcutaneously injected 
into the left rear flanks of female nude mice at a saturating con-
centration (2 × 106), aimed to ensure the development of tumor 
masses within a few weeks. Examination of palpable tumor 
lesions revealed that all (5/5) mice injected with vehicle-treated 
SUM-159 cells formed tumors 6 weeks after injection (Figure 4A). 
By contrast, in mice injected with SUM-159 cells pretreated with 
DOA, 20% (1/5) failed to develop tumors and 80% of injected 
animals (4/5) developed less macroscopically visible tumors. 
Indeed, the lesions in mice injected with DOA-pretreated cells 
were 15 times smaller in size than those observed in control 
animals (76 versus 1176 mm3; Figure 4A). Accordingly, the time 
required for 50% of animals to develop palpable tumors of either 
≥50 or ≥10 mm3 was lengthened by 78% (from 36 days with vehi-
cle-treated cells to 64 days with DOA-pretreated cells) and 119% 
(from 28 days with vehicle-treated cells to 64 days with DOA-
pretreated cells), respectively.
DOA suppresses the growth of CSC-enriched BC-cell 
populations in orthotopic implantation model
We next evaluated the ability of DOA to inhibit tumor formation 
using the orthotopic implantation of low numbers of SUM-159 
cells precultured under nonadherent and nondifferentiating 
conditions for 48 h, an experimental environment selecting for 
mammosphere-initiating CSC-like cells (Figure  4B). Single cell 
suspensions (5 × 103) isolated from these cultures were exposed 
or not to graded concentrations of DOA for 2 h before injection 
into the mammary fat pads of SCID/Beige mice. Examination 
of tumor formation revealed that all of the mice (5/5) injected 
with mammosphere-initiating SUM-159 cells formed tumors 9 
weeks after orthotopic injection (Figure 4B). By contrast, more 
than half of the mice (3/5) injected with mammosphere-ini-
tiating SUM-159 cells pretreated with the lowest dose of DOA 
(5  μmol/L) failed to develop visible tumors at the same time 
point. Accordingly, the time required for 50% of animals to 
develop palpable lesions ≥50 mm3 was lengthened by 155%, that 
is, from 47 days with vehicle-treated cells to 120 days with DOA-
treated cells (Figure 4B). Strikingly, all the mice (5/5) that were 
orthotopically injected with CSC-like SUM-159 cells pretreated 
with DOA at 10 or 20 μmol/L remained free from tumors more 
than 2 months after the control arm was ended (Figure 4B).
DOA regulates the expression of genes involved in 
stem cell fate
We designed secondary assays to gain some insights into the 
molecular mechanisms through which DOA might functionally 
deplete CSC-like states without promoting nonspecific cyto-
toxic effects on heterogeneous BC cell populations. First, we 
carried out a Stem Cell Transcription Factors Assay (TaqMan® 
OpenArray® Human Stem Cell Panel) to assess the impact of DOA 
on the expression of 609 stemness-related genes. A total of 160 
genes were found significantly altered in their baseline expres-
sion status (arbitrary fold-change cutoff of >2) when mono-
layer cultures of SUM-159 cells were cultured in the presence of 
20 μmol/L DOA for 3 days with daily refeeding of the compound 
(Supplementary Material, Table S1 and Figure S2, available at 
Carcinogenesis Online). Supporting the ALDEFLUOR inhibitory 
effect of DOA, ALDH1A1—the key ALDH isoenzyme-linked CSC 
function (40)—was among the genes significantly downregu-
lated (3-fold) by DOA. The expression of the CSC marker OCT4 
(8,9,41), a homeodomain transcription factor of the POU fam-
ily, was notably downregulated (4-fold) in the presence of DOA. 
DOA exposure drastically augmented the expression of WRN 
(13-fold), which has been shown to promote stem cell differen-
tiation via epigenetic inactivation of OCT4 (42). DOA treatment 
similarly augmented the expression of several suppressors of 
Figure 3. DOA specifically and potently decreases the mammosphere-initiating capacity of BC CSC-like states. (A) Representative ALDEFLUOR® assay to identify SUM-
159 cells with high ALDH activity (ALDH+) in the absence or presence of 20 μmol/L DOA for 3 days. The ALDH inhibitor DEAB was used as negative control. Monolayer 
cultures were fed with the DOA every other day. Results are representative of two technical replicates per n; n = 3 biological replicates. (B) Figure shows representative 
light microscope representations (×20 magnifications) of mammospheres formed by HMLERShEcad cells growing in sphere medium for 7 days in the absence or pres-
ence of graded concentrations of DOA. MSFE and MTT calculations were performed as described in Figure 2; three technical replicates per n; n = 3 biological replicates. 
(*P < 0.01 and **P < 0.001, statistically significant differences from the untreated (control) group; n.s. not statistically significant). (C) Anoikis-resistant cells obtained 
as described in Supplementary material, Materials and Methods, available at Carcinogenesis Online were cultured in DOA-free mammosphere medium for 7 days, and 
MSFE were calculated following the same procedure as that described in Figures 1 and 2; three technical replicates per n; n = 2 biological replicates.
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the undifferentiated metastatic phenotype (43,44) including 
SPRED1 (4-fold), SPRED2 (9-fold) and SMURF2 (7-fold).
DOA synergistically interacts with the mTOR 
inhibitor rapamycin and the DNMT inhibitor 
5-azacytidine
To further characterize the molecular targets through which 
DOA might exert its antistemness properties in cancer cell pop-
ulations, we utilized commercially available Biolog Phenotype 
MicroArrays (PM) for mammalian cells. This platform is com-
monly employed to analyze components of pathways that 
might be involved in resistance phenotypes, but its major role is 
for drug development by inference of the mechanism of action 
of a given compound (45–47). We simultaneously profiled SUM-
159 cells in four microplates (termed PM-M11, PM-M12, PM-M13 
and PM-M14) whose wells had been coated with antibiotics and 
other growth inhibitors to create 92 unique culture conditions. 
The PM assay was conducted over 2 days in the absence (negative 
plates) or presence (positive plates) of 20 μmol/L DOA, an opti-
mal concentration that fully impeded mammosphere forma-
tion but without cytotoxic effects against SUM-159 cells grown 
under adherent conditions (Figure 5A). DOA treatment appeared 
to strongly protect SUM-159 cells from the cytotoxic effects 
of the multifaceted alkaloid sanguinarine (48,49). Conversely, 
DOA was found to synergistically interact, in a dose-dependent 
manner, with the allosteric mTOR inhibitor rapamycin and the 
DNA methyltransferase (DNMT) inhibitor 5-azacytidine and in 
a dose-independent manner with the chemotherapeutic agent 
doxorubicin (Figure 5A). We therefore chose to further investi-
gate the metabolo-epigenetic nature of DOA in terms of its cap-
acity to target and inhibit mTOR and DNMT.
We first tested the ability of DOA to alter the phosphoryl-
ation status of the mTOR pathway kinase p70S6K1, a commonly 
used readout of mTOR signaling (50). The phosphorylation of 
p70S6K1 on Thr389 was suppressed by graded concentrations 
of DOA in a time- and dose-dependent manner (Figure 5B, left 
Figure 4. DOA blocks tumor-initiating capacity of CSC-like cells in vivo. (A) Tumor growth rate was calculated by measuring volumes along several weeks after injec-
tion of DOA-pretreated of untreated control cells. Shown are the mean volumes (±SD) for at least 9 weeks. Tumor-free survival in mice bearing SUM-159 xenografts 
with volumes ≥10 and ≥50 mm3 is shown as a function of time. [*P < 0.01 and **P < 0.001, statistically significant differences from the untreated (control) group; n.s. not 
statistically significant]. (B) Mammosphere-initiating cells were isolated and exposed to graded concentrations of DOA for 2 h. Viable single cell suspensions (1 × 104 
cells) were orthotopically injected into the mammary fat pads of SCID/Beige mice, and tumor growth was monitored for at least 4 months. Tumor-free survival in mice 
bearing orthotopically implanted SUM-159 CSC-like cells is shown as a function of time.
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panels). Moreover, DOA decreased the cellular activity of the 
mTOR kinase as early as 30  min after treatment, although to 
a lesser extent than that achieved by rapamycin. When total 
DNMT activity in nuclear extracts of SUM-159 cells pretreated 
with DOA for 2  h was assessed using an ELISA-based DNMT 
activity/inhibition assay, a ~30% reduction in DNMT activity was 
found in the presence of DOA (Figure 5B, right panels).
DOA is an ATP-competitive mTOR inhibitor
Biophenols structurally related to DOA such as quercetin have 
been suggested to inhibit the enzymatic activity of mTOR by 
bonding to its ATP-binding catalytic pocket (51). Given this 
information, we performed computational studies using sev-
eral cocrystal structures of a complex of mTOR with an ATP 
transition state mimic and with several ATP-site inhibitors: 
4JT6 (in complex with PI-103), 4JSX (in complex with Torin 2), 
4JT5 (in complex with PP242) and 4JSV/4JSP (in complex with 
ATPgamma-Mg2+). Results of in silico binding experiments using 
rigid-docking calculation, which were run twice to avoid false 
positives, showed that DOA bound all the above crystal struc-
tures with energies ranging from −6.0 kcal/mol for 4JSV to 
−7.1 kcal/mol for 4JT6, which was selected for further analysis 
(Supplementary Material, Table S2, available at Carcinogenesis 
Online). To add protein flexibility to the analysis and to test the 
stability of the selected DOA-mTOR complex, we carried out 
short MD simulations of 1 ns and applied MM/GBSA calcula-
tions to estimate a −26.8226 kcal/mol free energy of the binding 
of DOA to 4JT6 (Supplementary Material, Table S2, available at 
Carcinogenesis Online).
To characterize the mechanism of action of DOA against 
mTOR, we selected five different second-generation ATP-
competitive mTOR inhibitors (TORKinhibs): AZD2014 (vis-
tusertib), PP242 (torkinib), OSI-027, Torin 2 and NBP-BEZ235 
(dactolisib) to perform rigid docking, MD simulations and MM/
GBSA calculations (Figure  5C; Supplementary Material, Table 
S3, available at Carcinogenesis Online). The binding mode of 
DOA shared key amino acid residues of the binding modes of 
TORKinhibs and apparently mimicked the binding behavior of 
PP242 and Torin 2 to the ATP-binding catalytic pocket of mTOR, 
although the presence of more aromatic rings in the DOA mol-
ecule resulted in a slightly different binding strength from that 
of PP242 and Torin 2.  Specifically, rigid-docking calculations 
revealed that π–π stacking appears to occur between the aro-
matic ring of DOA and the Trp2239 residue (or Tyr2225 upon 
conformational changes of either DOA or the pocket itself) in 
the catalytic site of mTOR. A stronger stabilization of the DOA 
Figure 5. (A) DOA synergistically interacts with mTOR and DNMT inhibitors. Shown are representative microphotographs of PM arrays (microplates PM-M11–PM-M14) 
from two biological replicates. The different interactions were defined as described in Supplementary Material, available at Carcinogenesis Online. (B) DOA decreases 
mTOR and DNMT activities in cultured cells. Left. Representative western blotting analyses of phospho-p70 S6 Kinase (Thr389)/phospho-p85 S6 Kinase (Thr412) in 
SUM-159 cells cultured in the absence of presence of DOA or rapamycin for up to 6 h, as specified. Right. Nuclear extracts of SUM-159 were exposed to 20 μmol/L DOA 
for 2 h before assessing DNMT activity using the DNMT activity/Inhibition Assay Kit of Active Motif as per manufacturer’s instructions. The results are expressed as 
percentages of the means (columns) ± SD (bars); three technical replicates per n; n = 2 biological replicates. (**P < 0.001 versus DNMT activity in untreated nuclear 
extracts). (C) DOA binds the ATP-binding pocket in mTOR kinase domain and inhibits mTOR kinase activity. Overall structures and views of the interaction between 
DOA (red) and well-known TORKinhibs with the ATP-dependent catalytic pocket of mTOR (PDB code 4JT6). Figure shows in sticks all the interaction residues involved 
in the binding of DOA/TORKinhibs using PLIP. Hydrogen bond interactions are represented by orange dashed lines; salt bridges are represented by yellow dashed lines 
and charge centers by yellow spheres; Cation-π interactions are represented by blue dashed lines and white spheres for the center of the aromatic ring. (D) DOA dir-
ectly inhibits the ATP-dependent catalytic activity of mTOR. A dose-response curve of ATP-dependent mTOR kinase activity was created by plotting FRET signal of the 
Z′-LYTE Kinase assay as the function of DOA concentration.
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binding appeared to involve Gly2238 and Val2240, which not 
only might stabilize the Trp2239-DOA stacking but also estab-
lish direct electrostatic interactions with DOA (Supplementary 
Material, Table S4, available at Carcinogenesis Online). When we 
added the solvation effect and the dynamic nature of the inter-
action in the DOA–mTOR complex, the generated trajectories 
by MD simulations confirmed the main occurrence of the π-π 
stacking with Trp2239 (and a more fluctuating interaction with 
Tyr2225), as well as a significant number of additional residues 
performing key electrostatic interactions depending on the con-
formation adopted by the DOA–mTOR complex (Supplementary 
Material, Table S4, available at Carcinogenesis Online).
We then used the FRET-based Z-LYTE™ Kinase Assay to test 
the ability of DOA to inhibit mTOR activity. Ten concentrations 
of DOA spanning over five logarithmic decades were selected. To 
validate the bioassay procedure, we also measured the inhibi-
tory profile of the TORKinhibs PP242 and Torin 2.  Figure  5D 
shows the mTOR activity rate as a function of DOA concentra-
tion. DOA inhibited mTOR activity with an IC50 of 2.6  μmol/L, 
whereas the measured IC50 values for PP242 and Torin 2 were 
18.3 and 1.3  nmol/L, respectively (Supplementary Material, 
Figure S3, available at Carcinogenesis Online).
DOA is an SAM competitive inhibitor of DNMTs
We next performed computational studies using the crystal 
structure of human DNMT (351–1600) 4WXX (Figure 6A). In sil-
ico binding experiments employing rigid-docking calculations 
confirmed the ability of DOA to bind the DNMT/4WXX crystal 
structure with an energy of −7.8 kcal/mol. Short MD simulations 
and MM/GBSA estimated a −30.567 kcal/mol free energy of the 
binding of DOA to DNMT/4WXX (Supplementary Material, Table 
S2, available at Carcinogenesis Online). To characterize the mech-
anism of action of DOA against DNMT, we selected five DNMT 
inhibitors: 5-azacytidine, RG108, curcumin, SGI-110 and epigal-
locatechin gallate (Figure 6). Similarly to what happened with 
the binding mode of DOA to mTOR, the binding mode of DOA 
appeared to share that of all the chosen DNMT inhibitors with 
the presence of one or two more aromatic rings being respon-
sible for the differences in the free energy binding, which ranged 
from −20.4119 kcal/mol for RG108 to −40.1785 kcal/mol for epigal-
locatechin gallate (Supplementary Material, Table S3, available 
at Carcinogenesis Online). The DOA pattern of spatial orienta-
tion more closely resembles that of 5-azacytidine, SGI-110 and 
curcumin. Rigid-docking calculations and MD simulations sug-
gested that the main residues involved in the stabilization of the 
DOA-DNMT complex were Ser1146, Pro1125, Asp1143, Phe1145, 
Gly1150, Leu1151, Asn1158, Val1580 and Gly1223, along with a 
significant number of additional residues performing key elec-
trostatic interactions depending on the conformation adopted 
by the DOA–DNMT complex (Supplementary Material, Table S4, 
available at Carcinogenesis Online).
We then used an amplified luminescent proximity homoge-
neous assay (AlphaScreen) to in vitro test the ability of DOA to 
inhibit DNMT activity. As before, 10 concentrations of DOA over 
4 logarithmic decades were selected and tested in the presence 
of 20  μmol/L S-adenosyl-l-methionine (SAM), a catalytic sub-
strate of DNMTs. To validate the bioassay procedure, we also 
measured the inhibitory profile of the natural inhibitor of DNMT 
activity, S-adenosyl-l-homocysteine (SAH). Figure  6B shows 
the activity rates of DNMT1, DNMT3A/3L and DNMT3B/3L as a 
function of DOA concentration. DOA inhibited the methyltrans-
ferase activity of DNMT1, 3A/3L and 3B/3L with an IC50 of 11.5, 5.7 
and 5.2 μmol/L, respectively (Figure 6, bottom panels), whereas 
the measured IC50 values for SAH were 9.9, 5.8 and 2.8 μmol/L, 
respectively (Supplementary Material, Figure S4, available at 
Carcinogenesis Online).
DOA synergistically inhibits self-renewal capacity of 
CSC-like cells in combination with rapamycin and 
5-azacytidine
Given that mammosphere size reflects the self-renewal cap-
acity of each CSC-like cell, we used the recently developed 
Cell2Sphere™ Kit to evaluate the impact of DOA for self-renewal 
in combination with either rapamycin or 5-azacytidine. We used 
two in vitro models for this analysis: the MDA-MB-436 cell line 
is an M-like BC model that harbors the deleterious mutation 
5396  +  1G>A in the splice donor site of exon 20 of the BRCA1 
gene and the BT-474 cell line is a luminal-like BC model with 
an amplification of the HER2 oncogene. The size of MDA-MB-436 
and BT-474 mammospheres decreased significantly in the pres-
ence of graded concentrations of DOA (Figure  7A). Moreover, 
the concurrent supplementation with a suboptimal concen-
tration of DOA significantly enhanced the ability of rapamycin 
and 5-azacytidine to limit the size of MDA-MB-436 and BT-474 
mammospheres, indicating a reduction in self-renewal capacity. 
Under these conditions, mammospheres, when found, were 
considerably smaller than those generated from untreated con-
trol cultures, and there were no mammospheres >50 μm in size 
(Figure 7A).
Discussion
Advancement in cancer prevention and treatment may derive 
from the identification of molecules capable of eliminating 
tumor- and metastasis-initiating chemoresistant CSC. A poten-
tial approach to eliminate the polycausal and multidimensional 
genotype–phenotype interactions that drive CSC cellular states 
may involve the usage of multifaceted drugs capable of interfer-
ing with the biologic functioning of cancer stemness itself. Plant 
evolution has produced a rich source of refined, multitargeting 
phytochemicals to overcome environmental stresses, including 
protection against fungi, insects and predators. Not surprisingly, 
plant-derived phytochemicals targeting the multiple molecular 
machineries that support CSC cellular states are emerging as 
valuable tools for therapy. Here, we aimed to characterize the 
health benefits chemically encrypted in secoiridoids that are 
unique to oleaceous plants in terms of their bioactivity against 
CSC. Our systematic in vitro, in vivo and in silico approach 
(Figure 7B) reveals for the first time that EVOO contains a phe-
nol-conjugated oleosidic secoiridoid (DOA) capable of function-
ally depleting the CSC-like states responsible for maintaining 
tumor-initiating properties within genetically diverse types of 
BC populations.
In contrast to the target-based strategies that have been 
widely employed in the pharmaceutical cancer industry in the 
past decades, including those aimed to discover new anti-CSC 
drugs, we chose to uncover novel EVOO-derived anti-CSC bio-
phenols by employing a cell-based phenotypic drug discovery 
strategy coupled to mechanism-of-action profiling and target 
deconvolution (52,53). Without prior knowledge of the phenolic 
compound target(s), we first screened and selected a lead com-
pound from the EVOO phenolic fraction based on quantifiable 
phenotypic endpoints such as in vitro ALDH activity and mam-
mosphere formation, and in vivo tumor initiation. This experi-
mental approach identified DOA as a hitherto unrecognized 
anti-CSC phytochemical that, when used as single-agent at low 
micromolar concentrations, is sufficient to fully prevent the 
ability of CSC-like cellular states to survive and proliferate as 
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floating mammospheres under nonadherent and nondifferen-
tiating conditions. It is believed that the size of tumorspheres 
reflects self-renewal rate of stem cells. Consequently, the 
observed effects of DOA on both the number and size of mam-
mospheres point to its ability to not only target the tumor-initi-
ating traits possessed by CSC-like states but also to reduce their 
self-renewal capabilities. DOA has a null inhibitory effect on BC 
cell growth and viability under two-dimensional differentiated 
growth conditions, thus confirming that the DOA-responsive 
phenotype is exclusively manifested under three-dimensional 
stem cell culture conditions. Indeed, the substantial decrease 
in tumor initiation rates upon pre-exposure of BC cells to DOA 
prior to implantation in mice strongly supports the notion that 
DOA is particularly efficient at specifically removing CSC and 
preventing the occurrence of CSC-like cellular states from the 
bulk population of nontumorigenic cancer cells. Accordingly, 
treatment with noncytotoxic concentrations of DOA for only 2 h 
successfully impaired anoikis-resistant cancer cells with stem-
like characteristics from forming tumors in mammary fat pads 
even though the compound is presumably not present 4 months 
after injection. These findings lend experimental support to 
mathematical models proposing that CSC-targeted therapies 
are a better choice for long-term maintenance therapy via sup-
pression of CSC-driven tumor relapse in vivo, even when such 
therapies, as it is the case for DOA, might not exert cytotoxic 
effects in bulk cancer cell populations (54).
Despite the diversity of genetic changes and molecular aber-
rations driving the different molecular subtypes of BC (e.g., 
luminal, HER2-enriched, basal-like, claudin-low), it is known 
that CSC-like states within these distinct BC subtypes have 
similar gene expression patterns, suggesting common, shared 
regulatory signaling pathways in CSC subpopulations across 
the molecular subtypes of BC (13,33). DOA treatment induced 
specific and potent suppression of E- and M-CSC cellular states 
irrespective of the mutational landscape of the starting BC 
population, strongly suggesting that its mechanism of action 
might efficiently interfere with the biologic functioning of can-
cer stemness per se. To couple the phenotypic drug discovery 
Figure 6. DOA binds the DNA-binding pocket in DNMT methylation domain and inhibits SAM-dependent DNA methylation activity. (A) Overall structures and views 
of the interaction between DOA (red) and well-known DNMT inhibitors with the DNA-binding catalytic pocket of DNMT1 (PDB code 4WXX). Figure shows in sticks all 
the interaction residues involved in the binding of DOA/DNMT inhibitors as described in Figure 5. (B) Dose-response curves of SAM-dependent methylation activities 
of DNMT1, DNMT3A/3L and DNMT3B/3L were created by plotting AlphaScreen signals as the function of DOA concentration.
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of DOAgly anti-CSC activity and target deconvolution, we used 
mechanism-of-action profiling with PM-based screenings, 
which indicated synergistic interactions of DOA with the mTOR 
inhibitor rapamycin and the DNMT inhibitor 5-azacytidine. The 
statistically significant reduction in the number and size of 
mammospheres generated with DOA plus rapamycin or 5-aza-
cytidine would indicate that DOA functions synergistically to 
decrease the magnitude of the tumor-initiating CSC-like popu-
lations as well as their self-renewal capacity by, in part, targeting 
the rapamycin and 5-azacytidine molecular targets, mTOR and 
DNMT, respectively. Indeed, in silico computational approaches 
suggested that DOA binds and inhibits the ATP-binding kinase 
domain site in mTOR and the SAM cofactor-binding pocket in 
DNMTs. Consistent with this notion, FRET-based Z-LYTE™ and 
AlphaScreen-based in vitro assays confirmed its capacity to 
function as an ATP-competitive inhibitor that directly targets 
the mTOR catalytic site and to block the SAM-dependent methy-
lation activity of DNMTs.
The dual mTOR/DNMT inhibitory nature of DOA appears to 
target a highly relevant metabolo-epigenetic dimension that 
drives the functional traits of tumor-initiating CSC-like cells. 
Against this background, the translational landscape of mTOR 
signaling is beginning to be viewed as a key component of the 
protein synthesis-addicted metabolic profile of tumor-initiating 
CSC-like cells (55). Accordingly, administration of rapamycin 
efficiently suppresses the tumorsphere-forming potential of 
mammosphere formation of BCSC (56). Moreover, DNMT1 is 
essential for the self-renewal and maintenance of CSC, and thus 
5-azacytidine treatment during premalignant stages efficiently 
blocks mammary tumorigenesis and reduces tumorsphere-
forming potential of CSC (57). Our findings suggest that the 
DOA’s ability to strongly and negatively impact the tumorigenic 
and self-renewal nature of CSC occurs through DNMT-related 
epigenetic regulation in addition to the inhibition of the mTOR-
related anabolic phenotype of CSC. DOA turned off the expres-
sion of pivotal factors that positively regulate the activation of 
Figure 7. (A) DOA augments the capacity of mTOR inhibitor rapamycin and DNMT inhibitor 5-azacytidine to inhibit BC mammosphere formation activity. Cell2Sphere™ 
assays using BRCA1-deficient MDA-MB-436 (left) and HER2-overexpressing BT-474 cell (right) were performed as per the manufacturer’s instructions. Drugs were added 
to sextuplicate sets of wells on days 1 and 4 without replenishing the medium. ImageJ was used to quantify the size (central lines indicate mean values) of 6-day-old 
mammospheres. Size bar = 2000 μm. (B) EVOO-derived oleoside DOA is a metabolo-epigenetic suppressor of CSC cellular states: A phenotypic drug discovery approach. 
EVOO is the juice from fruits of olive trees (Olea europaea L.) obtained solely by mechanical means and consumed without further refining processes other than wash-
ing, filtration, decantation and centrifugation. Whereas well-known secoiridoids such as the glucoside oleuropein are characteristic and abundant constituents easily 
accessible from the drupes and other organs (leaves) of O. europaea L., DOA is an oleuropein-dialdehyde derivative confirmed only in EVOO in highly variable concentra-
tions. We performed a holistic approach of phenotypic drug discovery coupled to mechanism-of-action (MOA) functional profiling and target deconvolution that identi-
fied DOA as an unforeseen EVOO bioactive phytochemical that operates as a dual TORKinhib/DNMTinhib molecule capable of specifically and potently suppressing the 
functional traits of CSC irrespective of the mutational landscape of BC populations. 
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the CSC phenotype such as the stemness transcription factor 
OCT4 and the telomerase catalytic subunit TERT, while con-
comitantly augmented the expression of genes contributing to 
cell differentiation (e.g., FOS, CASP3) rather than execution of 
cell death programs (58–60). Therefore, it appears reasonable to 
suggest that DOA might functionally deplete tumor-initiating 
CSC-like states that sustain tumorigenicity by impacting fun-
damental controllers of cell fate choice, a metabolo-epigenetic 
mechanism involving both the downregulation of stemness-
driving transcription factors and the re-activation of epigenet-
ically suppressed differentiation programs.
Our discovery that EVOO, a unique functional food with 
a major contribution to the health-promoting effects of the 
Mediterranean diet (24–29), contains a natural inhibitor of mTOR 
and DNMTs capable of specifically and potently suppressing the 
functional traits of CSC within heterogeneous cancer cell popu-
lations, might open new avenues for introducing innovations in 
CSC-targeted therapy (61) based on the molecular bridge that 
connects metabolism and epigenetics with the state of stemness.
Supplementary material
Supplementary Material, Table S1–S4 and Figure S1–S3, can be 
found at Carcinogenesis online.
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